Lidocaïne Aguettant

Lidocaine Hydrochloride, the active ingredient in Lidocaïne Aguettant, is a local anesthetic (amide) presented as a sterile solution for infiltration, intradermal and intravenous use. It provides reversible loss of sensation in targeted tissues for minor surgical, diagnostic and regional anesthesia procedures. Its rapid onset and moderate duration make it suitable for procedures lasting from a few minutes to an hour.

GNH USA supplies Lidocaïne Aguettant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for global distribution.

Lidocaïne Aguettant is used as a local anesthetic to block nerve conduction in various procedural settings.

- Infiltration anesthesia: provides localized numbness for minor surgical or dental procedures - Intradermal anesthesia: enables pain‑free skin testing and minor dermatologic interventions - Intravenous regional anesthesia (Bier block): facilitates anesthesia of an extremity during orthopedic surgery - Peripheral nerve block: produces anesthesia of specific nerves for limb surgeries - Continuous infusion via catheter: maintains postoperative analgesia during recovery

Lidocaïne Aguettant may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Transient burning or tingling at the injection site - Mild dizziness or light‑headedness - Nausea or mild gastrointestinal upset - Hypotension when administered intravenously

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - Cardiac arrhythmias, including ventricular tachycardia - Methemoglobinemia leading to cyanosis - Central nervous system toxicity such as seizures or loss of consciousness

When using Lidocaïne Aguettant, clinicians should observe several precautionary measures to minimize risk.

- Allergy assessment: verify no known hypersensitivity to amide‑type local anesthetics - Cardiovascular status: avoid rapid IV bolus in patients with heart block or arrhythmias - Dosage monitoring: calculate dose based on patient weight and adhere to maximum recommended limits - Concurrent CNS depressants: use with caution when combined with other CNS‑active drugs - Pregnancy and lactation: use only if the anticipated benefit justifies potential risk, as safety data are limited - Store at ambient temperature: keep in original container, protect from light and moisture

Lidocaine can interact with other medicines, altering its plasma concentration or enhancing pharmacodynamic effects.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): may increase plasma lidocaine levels - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can raise lidocaine concentrations - Co‑administration with other local anesthetics: additive toxicity risk

Moderate Interactions (Monitor Closely): - Beta‑blockers: may potentiate hypotensive effects - General anesthetics (e.g., propofol, volatile agents): may enhance CNS depression - Loop diuretics (e.g., furosemide): may affect lidocaine clearance